Skip to main content

Advertisement

Table 2 Characteristics of ALT responders and non-responders

From: Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

  ALT responders (n = 15) ALT non-responders (n = 14) P-value
Age (year) 50.7 ± 12.1 61.7 ± 12.4 0.011
Male/female (n) 9 (6) 5 (9) 0.191
Dyslipidemia (%) 12 (80.0) 12 (85.7) 0.68
Statin (%) 4 (26.7) 8 (57.1) 0.10
Diabetes (%) 5 (33.3) 9 (64.3) 0.10
BMI (kg/m2) 26.5 ± 4.1 26.6 ± 3.8 0.47
FBS (mg/dL) 115.7 ± 37.9 121.4 ± 31.2 0.33
IRI (μU/mL) 23.5 ± 22.7 22.6 ± 38.0 0.47
HbA1c (%) 5.94 ± 1.03 6.9 ± 1.2 0.019
HDL cholesterol (mg/dL) 60.3 ± 18.6 49.7 ± 11.7 0.04
LDL cholesterol (mg/dL) 124.5 ± 33.1 102.9 ± 18.6 0.021
Triglycerides (mg/dL) 202.4 ± 164.1 187.6 ± 103.3 0.39
NEFA (μEq/L) 720.2 ± 285.0 563.3 ± 143.0 0.055
AST (IU/L) 46.3 ± 20.2 47.1 ± 14.1 0.45
ALT (IU/L) 77.1 ± 38.6 60.1 ± 32.2 0.104
GGT (IU/L) 81.9 ± 58.0 58.0 ± 26.6 0.085
Ferritin (ng/mL) 260.2 ± 164.5 176.6 ± 126.1 0.07
Platelet count (×104 /μL) 20.3 ± 4.6 21.3 ± 6.8 0.32
Type IV collagen 7 s 4.61 ± 1.13 5.59 ± 2.51 0.09
Glutathione in protein fraction (μM) 1.53 ± 0.92 1.27 ± 0.83 0.230
Glutathione in deprotenized fraction (μM) 0.017 ± 0.020 0.036 ± 0.057 0.116
CAP (db/m) 300.3 ± 41.1 290.4 ± 50.2 0.29
LSM (kPa) 8.71 ± 4.63 11.36 ± 5.05 0.080
  1. Data are expressed as mean ± standard deviation
  2. Abbreviations: BMI body mass index, FBS fasting blood sugar, IRI immunoreactive insulin, HBA1c hemoglobin A1c, HDL cholesterol high density lipoprotein cholesterol, LDL cholesterol low density lipoprotein cholesterol, NEFA non-esterified fatty acid, AST asparate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, CAP controlled attenuation parameter, LSM liver stiffness measurement